Cargando…

Fuzuloparib: First Approval

Fuzuloparib (AiRuiYi(®), 艾瑞颐; formerly fluzoparib) is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (formerly Jiangsu Hengrui Medicine Co., Ltd.) for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment...

Descripción completa

Detalles Bibliográficos
Autor principal: Lee, Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380563/
https://www.ncbi.nlm.nih.gov/pubmed/34118019
http://dx.doi.org/10.1007/s40265-021-01541-x